|
AR034257A1
(es)
|
2000-06-30 |
2004-02-18 |
Du Pont Pharm Co |
Compuesto ureido, composicion farmaceutica que lo comprende y metodo para modular la actividad del receptor de quimiocinas
|
|
EP1318811B1
(en)
|
2000-08-17 |
2006-08-30 |
Merck & Co., Inc. |
Cyclopentyl modulators of chemokine receptor activity
|
|
KR20040013090A
(ko)
|
2001-07-02 |
2004-02-11 |
아스트라제네카 아베 |
케모킨 수용체 활성의 조절자로서 유용한 피페리딘 유도체
|
|
EP1501507B1
(en)
|
2002-04-29 |
2008-05-28 |
Merck & Co., Inc. |
Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
|
|
US20060030582A1
(en)
|
2002-04-29 |
2006-02-09 |
Demartino Julie |
Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
|
|
MY129850A
(en)
|
2002-04-29 |
2007-05-31 |
Merck Sharp & Dohme |
Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
|
|
JP4459807B2
(ja)
|
2002-04-29 |
2010-04-28 |
メルク エンド カムパニー インコーポレーテッド |
テトラヒドロピラニルシクロペンチルテトラヒドロイソキノリン系のケモカイン受容体活性調節剤
|
|
WO2004041777A2
(en)
|
2002-10-30 |
2004-05-21 |
Merck & Co., Inc. |
Heteroarylpiperidine modulators of chemokine receptor activity
|
|
US7557120B2
(en)
|
2003-02-24 |
2009-07-07 |
Merck & Co., Inc. |
Aminocyclopentyl fused heterotricylicamide modulators of chemokine receptor activity
|
|
WO2004082682A1
(en)
|
2003-03-18 |
2004-09-30 |
Merck & Co. Inc. |
Amino cyclobutylamide modulators of chemokine receptor activity
|
|
KR20060003353A
(ko)
|
2003-04-15 |
2006-01-10 |
머크 앤드 캄파니 인코포레이티드 |
케모킨 수용체의벤족사지닐-아미도사이클로펜틸-헤테로사이클릭 조절제
|
|
CA2521625A1
(en)
|
2003-04-17 |
2004-11-04 |
Merck & Co., Inc. |
Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity
|
|
US20060205761A1
(en)
|
2003-06-06 |
2006-09-14 |
Catherine Abbadie |
Ccr-2 antagonists for treatment of neuropathic pain
|
|
AR045875A1
(es)
|
2003-10-27 |
2005-11-16 |
Merck & Co Inc |
Procedimiento para la preparacion del antagonista ccr-2
|
|
ATE517622T1
(de)
|
2003-10-27 |
2011-08-15 |
Merck Sharp & Dohme |
Salz eines tetrahydropyranylcyclopentyltetrahydropyridopyr diderivats als ccr-2 antagonisten
|
|
EP1701724A4
(en)
|
2004-01-02 |
2007-11-14 |
Merck & Co Inc |
ALKYLAMINO, ARYLAMINO AND SULFONAMIDOCYCLOPENTYLAMIDE MODULATORS OF THE ACTIVITY OF CHEMOKIN RECEPTORS
|
|
CA2555073A1
(en)
|
2004-02-12 |
2005-09-01 |
Merck & Co., Inc. |
Amino heterocyclic modulators of chemokine receptor activity
|
|
JP2007537264A
(ja)
|
2004-05-11 |
2007-12-20 |
インサイト コーポレイション |
ケモカインレセプタのモジュレータとしての３−（４−ヘテロアリールシクロヘキシルアミノ）シクロペンタンカルボキサミド
|
|
UY29219A1
(es)
|
2004-11-22 |
2006-04-28 |
Incyte Corp |
Sales de la n-(2- (((3r)-1-(trans-4-hidroxi-4-(6-metoxipiridin-3-il)-cilohexil) pirrolidin-3-il)amino)-2-oxoetil)-3- (trifluorometil) benzamida
|
|
CN101098700A
(zh)
|
2005-01-06 |
2008-01-02 |
默克公司 |
治疗炎性疾病的药物组合疗法和药用组合物
|
|
US8519135B2
(en)
|
2006-07-14 |
2013-08-27 |
Chemocentryx, Inc. |
Heteroaryl sulfonamides and CCR2/CCR9
|
|
US7671062B2
(en)
|
2006-07-28 |
2010-03-02 |
Bristol-Myers Squibb Company |
Modulators of chemokine receptor activity, crystalline forms and process
|
|
HRP20131167T1
(hr)
|
2007-06-18 |
2014-01-03 |
Merck Sharp & Dohme B.V. |
Antitijela za humani receptor programirane smrti pd-1
|
|
PL2175859T3
(pl)
|
2007-07-12 |
2012-09-28 |
Chemocentryx Inc |
Skondensowane heteroarylopirydylo- i fenylo-benzenosulfonamidy jako modulatory CCR2 do leczenia zapalenia
|
|
WO2009114335A2
(en)
|
2008-03-12 |
2009-09-17 |
Merck & Co., Inc. |
Pd-1 binding proteins
|
|
KR101814408B1
(ko)
|
2008-09-26 |
2018-01-04 |
다나-파버 캔서 인스티튜트 인크. |
인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도
|
|
WO2010068663A1
(en)
|
2008-12-10 |
2010-06-17 |
Janssen Pharmaceutica Nv |
4-azetidinyl-1-heteroaryl-cyclohexanol antagonists of ccr2
|
|
WO2010089411A2
(en)
|
2009-02-09 |
2010-08-12 |
Universite De La Mediterranee |
Pd-1 antibodies and pd-l1 antibodies and uses thereof
|
|
MX2011010919A
(es)
|
2009-04-16 |
2011-11-02 |
Janssen Pharmaceutica Nv |
Antagonistas del receptor 2 de citocina quimioatrayente de 4-azetidinil-1-heteroaril-ciclohexano.
|
|
CN102459227B
(zh)
|
2009-04-17 |
2014-08-20 |
詹森药业有限公司 |
Ccr2的4-氮杂环丁烷基-1-苯基-环己烷拮抗剂
|
|
ES2674275T3
(es)
|
2009-12-17 |
2018-06-28 |
Centrexion Therapeutics Corporation |
Antagonistas del receptor CCR2 y usos de los mismos
|
|
US9040526B2
(en)
|
2010-02-09 |
2015-05-26 |
Bristol-Myers Squibb Company |
Benzylpyrrolidinone derivatives as modulators of chemokine receptor activity
|
|
EP2569298B1
(en)
|
2010-05-12 |
2015-11-25 |
Boehringer Ingelheim International GmbH |
Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
|
|
US8642622B2
(en)
|
2010-06-16 |
2014-02-04 |
Bristol-Myers Squibb Company |
Piperidinyl compound as a modulator of chemokine receptor activity
|
|
TW201204717A
(en)
|
2010-06-17 |
2012-02-01 |
Janssen Pharmaceutica Nv |
Cyclohexyl-azetidinyl antagonists of CCR2
|
|
AU2012226890B2
(en)
|
2011-03-10 |
2016-10-06 |
Daiichi Sankyo Company, Limited |
Dispiropyrrolidine derivative
|
|
HRP20201595T1
(hr)
|
2011-11-28 |
2020-12-11 |
Merck Patent Gmbh |
Anti-pd-l1 protutijela i njihova uporaba
|
|
US8822460B2
(en)
|
2012-04-06 |
2014-09-02 |
Janssen Pharmaceutica Nv |
Fused cyclopentyl antagonists of CCR2
|
|
CN113967253A
(zh)
|
2012-05-15 |
2022-01-25 |
百时美施贵宝公司 |
通过破坏pd-1/pd-l1信号传输的免疫治疗
|
|
WO2013181452A1
(en)
|
2012-05-31 |
2013-12-05 |
Genentech, Inc. |
Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
|
|
HK1208236A1
(en)
*
|
2012-06-22 |
2016-02-26 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind ccr2
|
|
US9308236B2
(en)
|
2013-03-15 |
2016-04-12 |
Bristol-Myers Squibb Company |
Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
|
|
CA2915838C
(en)
*
|
2013-06-21 |
2023-04-18 |
Zenith Epigenetics Corp. |
Bicyclic bromodomain inhibitors
|
|
CA2920113A1
(en)
|
2013-08-20 |
2015-02-26 |
Merck Sharp & Dohme Corp. |
Treating cancer with a combination of a pd-1 antagonist and dinaciclib
|
|
JP6417419B2
(ja)
|
2013-09-04 |
2018-11-07 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
免疫調節剤として有用な化合物
|
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗ｐｄ-ｌ１之人類抗體
|
|
US9850225B2
(en)
|
2014-04-14 |
2017-12-26 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
|
TN2017000084A1
(en)
|
2014-09-11 |
2018-07-04 |
Bristol Myers Squibb Co |
Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1)/pd-li protein/protein interactions
|
|
US9732119B2
(en)
|
2014-10-10 |
2017-08-15 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US9856292B2
(en)
|
2014-11-14 |
2018-01-02 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US9861680B2
(en)
|
2014-12-18 |
2018-01-09 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US9944678B2
(en)
|
2014-12-19 |
2018-04-17 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US20160222060A1
(en)
|
2015-02-04 |
2016-08-04 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US9809625B2
(en)
|
2015-03-18 |
2017-11-07 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
ES2904252T3
(es)
|
2015-05-21 |
2022-04-04 |
Chemocentryx Inc |
Moduladores de CCR2
|
|
WO2017165125A1
(en)
*
|
2016-03-24 |
2017-09-28 |
Millennium Pharmaceuticals, Inc. |
Use of a pd-1 antagonist and an anti-ccr2 antibody in the treatment of cancer
|
|
US10251888B2
(en)
|
2016-06-13 |
2019-04-09 |
Chemocentryx, Inc. |
Method of treating pancreatic cancer
|
|
US10195188B2
(en)
|
2016-06-13 |
2019-02-05 |
Chemocentryx, Inc. |
Method of treating pancreatic cancer
|
|
WO2018005374A1
(en)
*
|
2016-06-27 |
2018-01-04 |
Chemocentryx, Inc. |
Immunomodulator compounds
|
|
CN118267479A
(zh)
|
2017-09-25 |
2024-07-02 |
凯莫森特里克斯股份有限公司 |
使用趋化因子受体2(ccr2)拮抗剂和pd-1/pd-l1抑制剂的联合治疗
|
|
US20190275015A1
(en)
|
2017-09-25 |
2019-09-12 |
Chemocentryx, Inc. |
Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor
|
|
US20190269664A1
(en)
|
2018-01-08 |
2019-09-05 |
Chemocentryx, Inc. |
Methods of treating solid tumors with ccr2 antagonists
|